NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 195.86 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.69
▼ -0.07 (-3.98%)

This chart shows the closing price for SPPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spectrum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPPI

Analyst Price Target is $5.00
▲ +195.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Spectrum Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 195.86% upside from the last price of $1.69.

This chart shows the closing price for SPPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Spectrum Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2021B. RileyReiterated RatingBuyHigh
9/20/2021JMP SecuritiesReiterated RatingBuy$4.00High
8/18/2021B. RileyLower Price TargetBuy$8.00 ➝ $6.00High
4/12/2021B. RileyReiterated RatingBuy$8.00High
10/26/2020HC WainwrightLower Price TargetBuy$13.00 ➝ $12.00High
9/17/2020JMP SecuritiesInitiated CoverageOutperform$12.00High
8/11/2020HC WainwrightReiterated RatingBuy$13.00High
8/3/2020HC WainwrightBoost Price TargetBuy$11.00 ➝ $13.00Medium
7/28/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Neutral$4.00 ➝ $7.00High
7/2/2020B. RileyReiterated RatingBuy$8.00N/A
6/22/2020B. RileyReiterated RatingBuy$8.00High
3/2/2020B. RileyLower Price TargetBuy$11.00 ➝ $8.00Medium
12/27/2019B. RileyLower Price TargetBuy$18.00 ➝ $11.00High
12/26/2019GuggenheimDowngradeBuy ➝ NeutralN/A
12/26/2019HC WainwrightInitiated CoverageBuy$41.00 ➝ $11.00N/A
12/26/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$17.00 ➝ $4.00N/A
11/27/2019B. RileyInitiated CoverageBuy$18.00Medium
10/25/2019HC WainwrightReiterated RatingBuyHigh
8/23/2019B. RileySet Price TargetBuy$18.00High
7/11/2019B. RileyInitiated CoverageBuy ➝ Buy$18.00Medium
5/13/2019GuggenheimInitiated CoverageBuy$19.00High
3/15/2019Jefferies Financial GroupReiterated RatingBuy ➝ Buy$21.00High
2/7/2019Cantor FitzgeraldInitiated CoverageOverweight$19.00High
1/10/2019HC WainwrightReiterated RatingBuy$40.00High
12/20/2018B. RileyLower Price TargetBuy$21.00High
11/12/2018B. RileyLower Price TargetBuy ➝ Buy$35.00 ➝ $29.00High
9/6/2018HC WainwrightBoost Price TargetBuy$40.00High
8/31/2018B. RileyBoost Price TargetBuy ➝ Buy$26.00 ➝ $35.00Medium
6/29/2018HC WainwrightReiterated RatingBuy$33.00Low
2/5/2018HC WainwrightBoost Price TargetPositive ➝ Buy$33.00High
12/18/2017HC WainwrightReiterated RatingBuy$29.00High
12/18/2017B. RileyInitiated CoverageBuy ➝ Buy$26.00High
11/3/2017HC WainwrightReiterated RatingBuyN/A
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/A
10/20/2017Jefferies Financial GroupBoost Price TargetBuy$25.00N/A
10/18/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $29.00N/A
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$13.00 ➝ $18.00N/A
9/25/2017Jefferies Financial GroupBoost Price TargetBuy$9.00 ➝ $13.00High
9/14/2017HC WainwrightReiterated RatingBuy$14.00Low
8/25/2017Jefferies Financial GroupSet Price TargetBuy$9.00Medium
8/16/2017HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
6/8/2017Jefferies Financial GroupSet Price TargetBuy$9.00Low
5/6/2017HC WainwrightSet Price TargetBuy$10.00High
5/3/2017Jefferies Financial GroupBoost Price TargetBuy$8.50 ➝ $9.00Medium
4/6/2017Jefferies Financial GroupReiterated RatingBuy$8.50Low
4/1/2017FBR & Co.Reiterated RatingBuyMedium
3/24/2017Jefferies Financial GroupReiterated RatingBuy$7.50Low
3/11/2017HC WainwrightSet Price TargetBuy$10.00Medium
3/11/2017FBR & Co.Set Price TargetBuy$11.00Medium
2/10/2017Jefferies Financial GroupInitiated CoverageHold ➝ Buy$8.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/29/2021
  • 14 very positive mentions
  • 8 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
10/28/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More

Today's Range

Now: $1.69
Low: $1.67
High: $1.80

50 Day Range

MA: $2.04
Low: $1.69
High: $2.43

52 Week Range

Now: $1.69
Low: $1.67
High: $5.24

Volume

4,123,100 shs

Average Volume

2,712,433 shs

Market Capitalization

$277.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Spectrum Pharmaceuticals?

The following equities research analysts have issued reports on Spectrum Pharmaceuticals in the last twelve months: B. Riley, JMP Securities, and Zacks Investment Research.
View the latest analyst ratings for SPPI.

What is the current price target for Spectrum Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Spectrum Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 195.9%. B. Riley has the highest price target set, predicting SPPI will reach $6.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $4.00 for Spectrum Pharmaceuticals in the next year.
View the latest price targets for SPPI.

What is the current consensus analyst rating for Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPPI will outperform the market and that investors should add to their positions of Spectrum Pharmaceuticals.
View the latest ratings for SPPI.

What other companies compete with Spectrum Pharmaceuticals?

How do I contact Spectrum Pharmaceuticals' investor relations team?

Spectrum Pharmaceuticals' physical mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company's listed phone number is (702) 835-6300 and its investor relations email address is [email protected] The official website for Spectrum Pharmaceuticals is www.sppirx.com.